Clinical trial

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

NCT02694263

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-07-01

PhasePHASE4

Study timeline

Study start (actual)2016-07-01Date precision: month

Registry last updated2020-01-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 2unresolved

Interventions

CanagliflozinDRUG · verified · RxNorm: canagliflozin

RepaglinideDRUG · verified · RxNorm: repaglinide

PioglitazoneDRUG · verified · RxNorm: pioglitazone

GliclazideDRUG

GlimepirideDRUG · verified · RxNorm: glimepiride

Sponsors & collaborators

University of Leicesterlead sponsor

University Hospital Birminghamcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02694263 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.